Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 15% Improvement Relative Risk HCQ for COVID-19  Shoaibi et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 29,451 patients in the USA Lower mortality with HCQ (p=0.001) c19hcq.org Shoaibi et al., medRxiv, September 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%).
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5,047 (13.6%), control 3,923 of 24,404 (16.1%), NNT 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, preprint, 5 authors.
This PaperHCQAll
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
PhD Azza Shoaibi, PharmD Stephen Fortin, MS Rachel Weinstein, Jesse A Berlin, PhD Patrick Ryan
doi:10.1101/2020.09.23.20199463
All authors contributed to the conceptualization and design of the study. SF authored the protocol of the study design, AS implemented the statistical analysis, RW, PBR and JB reviewed and approved the study diagnostics and results. AS drafted the manuscript and all coauthors reviewed and contributed to the manuscript writing. .
References
Austin, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Communications in statistics-simulation and computation
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life sciences
Cheung, Hung, Leung, Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study, Gastroenterology
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology
Howden, Tytgat, The tolerability and safety profile of famotidine, Clinical therapeutics
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy, J Biol Regul Homeost Agents
Malone, Tisdall, Smith, COVID-19: Famotidine, histamine, mast cells, and mechanisms
Mather, Seip, Mckay, Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, Official journal of the American College of Gastroenterology| ACG
Suchard, Schuemie, Krumholz, Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis, The Lancet
Walker, Patrick, Lauer, A tool for assessing the feasibility of comparative effectiveness research, Comp Eff Res
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2023, 3, 16]], 'date-time': '2023-03-16T12:51:00Z', 'timestamp': 1678971060070}, 'posted': {'date-parts': [[2020, 9, 24]]}, 'group-title': 'Gastroenterology', 'reference-count': 13, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 9, 24]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Famotidine ' 'has been posited as a potential treatment for COVID-19. We compared the incidence of COVID-19 ' 'outcomes (i.e., death; and death or intensive services use) among hospitalized famotidine ' 'users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine ' 'non-users separately.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We ' 'constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic ' 'health records. Study population were COVID-19 hospitalized patients aged 18 years or older. ' 'Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any ' 'medication containing one of the three drugs on the day of admission. The famotidine non-user ' 'group was derived from the same source population with no history of exposure to any drug ' 'with famotidine as an active ingredient prior to or on the day of admission. Time-at-risk was ' 'defined based on the intention-to-treat principle starting 1 day after admission to 30 days ' 'after admission. For each study comparison group, we fit a propensity score (PS) model ' 'through large-scale regularized B logistic regression. The outcome was modeled using a ' 'survival model.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We ' 'identified 2193 users of PPI, 5950 users of the hydroxychloroquine, 1816 users of famotidine ' 'and 26,820 non-famotidine users. After PS stratification, the hazard ratios for death were as ' 'follows: famotidine vs no famotidine HR 1.03 (0.89-1.18); vs PPIs: HR 1.14 (0.94-1.39); vs ' 'hydroxychloroquine:1.03 (0.85-1.24). Similar results were observed for the risk of death or ' 'intensive services ' 'use.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We found no ' 'evidence of a reduced risk of COVID-19 outcomes among hospitalized COVID-19 patients who used ' 'famotidine compared to those who did not or compared to PPI or hydroxychloroquine ' 'users.</jats:p></jats:sec>', 'DOI': '10.1101/2020.09.23.20199463', 'type': 'posted-content', 'created': {'date-parts': [[2020, 9, 24]], 'date-time': '2020-09-24T15:00:17Z', 'timestamp': 1600959617000}, 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6976-2594', 'authenticated-orcid': False, 'given': 'Azza', 'family': 'Shoaibi', 'sequence': 'first', 'affiliation': []}, {'given': 'Stephen', 'family': 'Fortin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rachel', 'family': 'Weinstein', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9810-745X', 'authenticated-orcid': False, 'given': 'Jesse A.', 'family': 'Berlin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrick', 'family': 'Ryan', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021021109351118000_2020.09.23.20199463v1.1', 'doi-asserted-by': 'crossref', 'unstructured': 'Malone RW , Tisdall P , Fremont-Smith P , et al. COVID-19: Famotidine, ' 'histamine, mast cells, and mechanisms. 2020.', 'DOI': '10.21203/rs.3.rs-30934/v1'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.2', 'doi-asserted-by': 'crossref', 'first-page': '36', 'DOI': '10.1016/S0149-2918(96)80177-9', 'article-title': 'The tolerability and safety profile of famotidine', 'volume': '18', 'year': '1996', 'journal-title': 'Clinical therapeutics'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.23812/Editorial-Conti-3'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.4', 'doi-asserted-by': 'crossref', 'unstructured': 'Wu C , Liu Y , Yang Y , et al. Analysis of therapeutic targets for ' 'SARS-CoV-2 and discovery of potential drugs by computational methods. ' 'Acta Pharmaceutica Sinica B 2020.', 'DOI': '10.1016/j.apsb.2020.02.008'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.5', 'first-page': 'PL365', 'article-title': 'The effect of histamine type 2 receptor antagonists on human ' 'immunodeficiency virus (HIV) replication: identification of a new class ' 'of antiviral agents', 'volume': '59', 'year': '1996', 'journal-title': 'Life sciences'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.6', 'doi-asserted-by': 'crossref', 'unstructured': 'Freedberg DE , Conigliaro J , Wang TC , et al. Famotidine use is ' 'associated with improved clinical outcomes in hospitalized COVID-19 ' 'patients: A propensity score matched retrospective cohort study. ' 'Gastroenterology 2020.', 'DOI': '10.1053/j.gastro.2020.05.053'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.7', 'doi-asserted-by': 'crossref', 'unstructured': 'Mather JF , Seip RL , McKay RG . Impact of Famotidine Use on Clinical ' 'Outcomes of Hospitalized Patients With COVID-19. Official journal of the ' 'American College of Gastroenterology| ACG 2020.', 'DOI': '10.14309/ajg.0000000000000832'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Janowitz T , Gablenz E , Pattinson D , et al. Famotidine use and ' 'quantitative symptom tracking for COVID-19 in non-hospitalised patients: ' 'a case series. Gut 2020.', 'DOI': '10.1158/1557-3265.COVID-19-S04-01'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.9', 'doi-asserted-by': 'crossref', 'unstructured': 'Cheung KS , Hung IF , Leung WK . Association between famotidine use and ' 'COVID-19 severity in Hong Kong: a territory-wide study. Gastroenterology ' '2020.', 'DOI': '10.1053/j.gastro.2020.05.098'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.10', 'unstructured': 'Premier Healthcare Database: Data That Informs and Performs. Premier ' 'website. ' 'https://products.premierinc.com/downloads/PremierHealthcareDatabaseWhitepaper.pdf..'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.11', 'first-page': '11', 'article-title': 'A tool for assessing the feasibility of comparative effectiveness ' 'research', 'volume': '2013', 'year': '2013', 'journal-title': 'Comp Eff Res'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/03610910902859574'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.13', 'doi-asserted-by': 'crossref', 'first-page': '1816', 'DOI': '10.1016/S0140-6736(19)32317-7', 'article-title': 'Comprehensive comparative effectiveness and safety of first-line ' 'antihypertensive drug classes: a systematic, multinational, large-scale ' 'analysis', 'volume': '394', 'year': '2019', 'journal-title': 'The Lancet'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.09.23.20199463', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 2, 15]], 'date-time': '2021-02-15T03:30:53Z', 'timestamp': 1613359853000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.09.23.20199463'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9, 24]]}, 'references-count': 13, 'URL': 'http://dx.doi.org/10.1101/2020.09.23.20199463', 'relation': {}, 'published': {'date-parts': [[2020, 9, 24]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit